ASX - By Stock
|
SNT |
Re:
SNT JustStocks Video on YouTube
|
|
melbstorm
|
34 |
6.4K |
3 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
34
|
6.4K
|
3
|
|
ASX - By Stock
|
SNT |
Re:
Syntara the science explained
|
|
melbstorm
|
10 |
1.7K |
3 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
10
|
1.7K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
melbstorm
|
250 |
61K |
1 |
12/05/24 |
12/05/24 |
ASX - By Stock
|
250
|
61K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
melbstorm
|
250 |
61K |
5 |
12/05/24 |
12/05/24 |
ASX - By Stock
|
250
|
61K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
melbstorm
|
239 |
63K |
18 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
239
|
63K
|
18
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
melbstorm
|
1.4K |
354K |
24 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
1.4K
|
354K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
PAA Chart
|
|
melbstorm
|
283 |
75K |
20 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
283
|
75K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust brand name required
|
|
melbstorm
|
30 |
6.1K |
13 |
28/12/23 |
28/12/23 |
ASX - By Stock
|
30
|
6.1K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
melbstorm
|
355 |
68K |
10 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
355
|
68K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Bella's Monepantel Trial
|
|
melbstorm
|
127 |
27K |
7 |
29/03/23 |
29/03/23 |
ASX - By Stock
|
127
|
27K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Interactive AGM Yes/No vote
|
|
melbstorm
|
87 |
12K |
8 |
15/02/23 |
15/02/23 |
ASX - By Stock
|
87
|
12K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient in US Canine Cancer Trials Begins Treatment
|
|
melbstorm
|
98 |
18K |
11 |
16/09/22 |
16/09/22 |
ASX - By Stock
|
98
|
18K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient in US Canine Cancer Trials Begins Treatment
|
|
melbstorm
|
98 |
18K |
10 |
16/09/22 |
16/09/22 |
ASX - By Stock
|
98
|
18K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
melbstorm
|
1.4K |
372K |
5 |
01/09/22 |
01/09/22 |
ASX - By Stock
|
1.4K
|
372K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
melbstorm
|
1.4K |
372K |
9 |
01/09/22 |
01/09/22 |
ASX - By Stock
|
1.4K
|
372K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Interesting Budget Item on Recycling
|
|
melbstorm
|
25 |
4.3K |
4 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
25
|
4.3K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Interesting Budget Item on Recycling
|
|
melbstorm
|
25 |
4.3K |
3 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
25
|
4.3K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
melbstorm
|
1.4K |
372K |
7 |
08/03/22 |
08/03/22 |
ASX - By Stock
|
1.4K
|
372K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
melbstorm
|
1.4K |
372K |
11 |
23/12/21 |
23/12/21 |
ASX - By Stock
|
1.4K
|
372K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
melbstorm
|
1.4K |
372K |
2 |
22/12/21 |
22/12/21 |
ASX - By Stock
|
1.4K
|
372K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
melbstorm
|
1.4K |
372K |
10 |
22/12/21 |
22/12/21 |
ASX - By Stock
|
1.4K
|
372K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
melbstorm
|
1.4K |
372K |
13 |
20/12/21 |
20/12/21 |
ASX - By Stock
|
1.4K
|
372K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
The Home Stretch
|
|
melbstorm
|
360 |
81K |
16 |
15/09/21 |
15/09/21 |
ASX - By Stock
|
360
|
81K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
melbstorm
|
197 |
34K |
14 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
197
|
34K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
melbstorm
|
732 |
144K |
2 |
17/05/21 |
17/05/21 |
ASX - By Stock
|
732
|
144K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
melbstorm
|
732 |
144K |
8 |
17/05/21 |
17/05/21 |
ASX - By Stock
|
732
|
144K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Why is our SP so low?
|
|
melbstorm
|
38 |
8.8K |
3 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
38
|
8.8K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Animal cancer annihilater > TumourPantel - When our fury friends need saving
|
|
melbstorm
|
8 |
2.1K |
9 |
09/04/21 |
09/04/21 |
ASX - By Stock
|
8
|
2.1K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs
|
|
melbstorm
|
56 |
11K |
6 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
56
|
11K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Relegating 2020 to hindsight, welcome 2021
|
|
melbstorm
|
20 |
4.9K |
4 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
20
|
4.9K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Virtual Investor Briefing
|
|
melbstorm
|
113 |
22K |
4 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
113
|
22K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Phase IIb Pet Dog Cancer Trial
|
|
melbstorm
|
45 |
8.7K |
2 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
45
|
8.7K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Virtual Investor Briefing
|
|
melbstorm
|
113 |
22K |
6 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
113
|
22K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Virtual Investor Briefing
|
|
melbstorm
|
113 |
22K |
14 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
113
|
22K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Virtual Investor Briefing
|
|
melbstorm
|
113 |
22K |
23 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
113
|
22K
|
23
|
|